|Bid||109.27 x 800|
|Ask||109.31 x 1100|
|Day's Range||108.80 - 110.13|
|52 Week Range||70.92 - 110.13|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||80.99|
|Earnings Date||Jul 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.10|
Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Edwards Lifesciences (NYSE: EW) today announced that clinical and economic results from the 3M (multidisciplinary, multimodality, but minimalist) Transcatheter Aortic Valve Replacement (TAVR) Economic Study and the PARTNER 3 Bicuspid Registry for SAPIEN 3 TAVR Study were presented at TVT 2021: The Structural Heart Summit.
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2021 after the market closes on Thursday, July 29, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those results.